CA
ABUS icon

Clearstead Advisors’s Arbutus Biopharma ABUS Stock Holding History

Clearstead Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$120 Buy
+25
New +$110 ﹤0.01% 3323

Other funds holding ABUS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
FCH
Freestone Capital Holdings Seattle, Washington $3.86B AUM 26.3% 1-Year Est. Return
LWA
Ledgewood Wealth Advisors Exeter, New Hampshire $188M AUM 18.45% 1-Year Est. Return
CCA
Carrera Capital Advisors Troy, Michigan $675M AUM 17.92% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.91B AUM 17.57% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Clearstead Advisors's ABUS Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Arbutus Biopharma (ABUS) in Q2 2026: 25 shares worth $120. The stake represents ﹤0.01% of the portfolio and ranks #3323 among its holdings.

51 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Clearstead Advisors held 25 shares of Arbutus Biopharma worth $120 as of Q2 2026.
  • Arbutus Biopharma was a new Clearstead Advisors position in Q2 2026.
  • Arbutus Biopharma made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3323 holding.
  • 51 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.